When SGLT2 inhibitors were introduced to Japan, where elderly patients with type 2 diabetes account for much of the population [10, 11], there were concerns about drug-related adverse events (AEs), such as fluid depletion and cerebral infarction. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.